Vazegepant
Mar 24, 2020
Thermo’s investment; Biohaven’s vazegepant Phase III trial; Cumberland’s aid
Thermo Fisher Scientific has announced to invest a hefty amount worth USD 800 Million across pharma manufacturing and services. The company plans to expand its capabilities in pharma manufacturing and services in the coming two years, with USD 475 Million reserved for 2020. The company has been acquirin...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
